ARTICLE | Company News
Celtaxsys Inc., Estrellita deal
January 16, 2012 8:00 AM UTC
Celtaxsys acquired exclusive, worldwide rights from Estrellita to CTX-4430. The company plans to begin a Phase I trial of the leukotriene A4 hydrolase (LTA4H) inhibitor to treat lung inflammation in...